ADC Therapeutics (ADCT) Stock Statistics & Valuation Metrics

ADC Therapeutics has a market cap or net worth of $196.61M. The enterprise value is $64.32M.

Market Cap

$196.61M

Enterprise Value

$64.32M

ADC Therapeutics has 127,667,694 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

127,667,694

Owned by Insiders

22.63%

Owned by Institutions

10.66%

ADC Therapeutics’s return on equity (ROE) is 0.77 and return on invested capital (ROIC) is -42.29%.

Return on Equity (ROE)

0.77

Return on Assets (ROA)

-0.44

Return on Invested Capital (ROIC)

-42.29%

Return on Capital Employed (ROCE)

-0.43

Revenue Per Employee

425.95K

Profits Per Employee

-746.72K

Employee Count

191

Asset Turnover

0.25

Inventory Turnover

1.83

The current PE Ratio of ADC Therapeutics is -2.34. ADC Therapeutics’s PEG ratio is -0.02.

PE Ratio

-2.34

PS Ratio

2.51

PB Ratio

-1.05

Price to FCF

-1.93

Price to Operating Cash Flow

-2.35

PEG Ratio

-0.02

In the last 12 months, ADC Therapeutics had revenue of 81.36M and earned -142.62M in profits. Earnings per share was -1.12.

Revenue

81.36M

Gross Profit

73.68M

Operating Income

-108.38M

Pretax Income

-142.78M

Net Income

-142.62M

EBITDA

-89.27M

Earnings Per Share (EPS)

-1.12

In the last 12 months, operating cash flow was -102.27M and capital expenditures -45,627, giving a free cash flow of -102.31M billion.

Operating Cash Flow

-102.27M

Free Cash Flow

-102.31M

Free Cash Flow per Share

-0.66

ADC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-51.87%

Earnings Yield

-40.46%

Beta

2.54

52-Week Price Change

-62.92%

50-Day Moving Average

1.31

200-Day Moving Average

2.46

Relative Strength Index (RSI)

54.74

Average Volume (3m)

1.56M

ADC Therapeutics upcoming earnings date is Nov 10, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 13, 2026

Next Earnings Date

Nov 10, 2026

Ex-Dividend Date

―

ADC Therapeutics as a current ratio of 4.37, with Debt / Equity ratio of -236.24%

Current Ratio

4.37

Quick Ratio

4.31

Debt to Market Cap

0.98

Net Debt to EBITDA

-1.99

Interest Coverage Ratio

-2.10

In the past 12 months, ADC Therapeutics has paid -157.00K in taxes.

Income Tax

-157.00K

Effective Tax Rate

0.00

ADC Therapeutics EV to EBITDA ratio is -4.51, with an EV/FCF ratio of -3.86.

EV to Sales

5.02

EV to EBITDA

-4.51

EV to Free Cash Flow

-3.86

EV to Operating Cash Flow

-3.86

ADC Therapeutics has $219.11M in cash and marketable securities with $417.11M in debt, giving a net cash position of -$198.00M billion.

Cash & Marketable Securities

$219.11M

Total Debt

$417.11M

Net Cash

-$198.00M

Net Cash Per Share

-$1.55

Tangible Book Value Per Share

-$1.47

Gross margin is 88.75%, with operating margin of -125.83%, and net profit margin of -123.03%.

Gross Margin

88.75%

Operating Margin

-125.83%

Pretax Margin

-123.55%

Net Profit Margin

-123.03%

EBITDA Margin

-111.21%

EBIT Margin

-111.65%

The average price target for ADC Therapeutics is $3.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$3.50

Price Target Upside

125.81% Upside

Analyst Consensus

Moderate Buy

Analyst Count

2

Revenue Growth Forecast

3.03%

EPS Growth Forecast

57.71%

Smart Score

4

AI Score

47